Biotech Stock
Capricor Stock Skyrockets 500% After Landmark HOPE-3 Trial Success: What’s Next for CAPR?
Capricor Therapeutics (NASDAQ: CAPR) saw its stock surge over 500% after announcing pivotal HOPE-3 Phase 3 trial results for Deramiocel in Duchenne muscular dystrophy. The trial’s success marks a potential turning point for the company’s regulatory path, finances, and future…
Spruce Biosciences Surges on FDA Breakthrough: Is SPRB’s Rally Sustainable?
Spruce Biosciences (SPRB) stock soared after its lead therapy for Sanfilippo Syndrome Type B received FDA Breakthrough Therapy status. But can the momentum last amid financial strain and execution risks?